BR112022001476A2 - Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit - Google Patents
Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kitInfo
- Publication number
- BR112022001476A2 BR112022001476A2 BR112022001476A BR112022001476A BR112022001476A2 BR 112022001476 A2 BR112022001476 A2 BR 112022001476A2 BR 112022001476 A BR112022001476 A BR 112022001476A BR 112022001476 A BR112022001476 A BR 112022001476A BR 112022001476 A2 BR112022001476 A2 BR 112022001476A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- dengue
- vaccine composition
- hepatitis
- unit dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IDP00201907241 | 2019-08-16 | ||
| US16/561,953 US11590221B2 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| EP19195692.9A EP3620174B1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| PCT/US2019/049749 WO2020051334A1 (en) | 2018-09-05 | 2019-09-05 | Dengue vaccine unit dose and administration thereof |
| PCT/US2020/020991 WO2021034349A1 (en) | 2019-08-16 | 2020-03-04 | Methods for preventing dengue and hepatitis a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001476A2 true BR112022001476A2 (pt) | 2023-10-03 |
Family
ID=74660757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001476A BR112022001476A2 (pt) | 2019-08-16 | 2020-03-04 | Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4013451A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7731344B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220049023A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114555113A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2020331884B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001476A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147807A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001742A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550261A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034349A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260167703A1 (en) * | 2022-11-02 | 2026-06-18 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
| DK2054428T3 (da) | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| TWI852899B (zh) * | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| EP3316905A1 (en) * | 2015-07-03 | 2018-05-09 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| TWI766876B (zh) | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
-
2020
- 2020-03-04 WO PCT/US2020/020991 patent/WO2021034349A1/en not_active Ceased
- 2020-03-04 PH PH1/2022/550261A patent/PH12022550261A1/en unknown
- 2020-03-04 AU AU2020331884A patent/AU2020331884B2/en active Active
- 2020-03-04 EP EP20719243.6A patent/EP4013451A1/en active Pending
- 2020-03-04 MX MX2022001742A patent/MX2022001742A/es unknown
- 2020-03-04 KR KR1020227008716A patent/KR20220049023A/ko active Pending
- 2020-03-04 CN CN202080071928.2A patent/CN114555113A/zh active Pending
- 2020-03-04 JP JP2022509723A patent/JP7731344B2/ja active Active
- 2020-03-04 BR BR112022001476A patent/BR112022001476A2/pt unknown
- 2020-03-04 CA CA3147807A patent/CA3147807A1/en active Pending
-
2024
- 2024-10-09 JP JP2024177535A patent/JP2025032070A/ja active Pending
-
2025
- 2025-04-23 AU AU2025202876A patent/AU2025202876B2/en active Active
-
2026
- 2026-04-15 AU AU2026202847A patent/AU2026202847A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026202847A1 (en) | 2026-05-07 |
| WO2021034349A1 (en) | 2021-02-25 |
| JP2022544613A (ja) | 2022-10-19 |
| JP2025032070A (ja) | 2025-03-11 |
| AU2020331884B2 (en) | 2025-01-23 |
| KR20220049023A (ko) | 2022-04-20 |
| PH12022550261A1 (en) | 2023-06-26 |
| AU2025202876B2 (en) | 2026-01-29 |
| MX2022001742A (es) | 2022-04-07 |
| EP4013451A1 (en) | 2022-06-22 |
| CN114555113A (zh) | 2022-05-27 |
| CA3147807A1 (en) | 2021-02-25 |
| AU2020331884A1 (en) | 2022-03-03 |
| AU2025202876A1 (en) | 2025-07-03 |
| JP7731344B2 (ja) | 2025-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024007274A2 (es) | Vacunas contra el metapneumovirus humano | |
| PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
| CO2023005373A2 (es) | Proteínas f de hmpv estabilizadas por prefusión | |
| BR112022017308A2 (pt) | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral | |
| CR20210201A (es) | Nuevos compuestos antihelmínticos | |
| BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| BRPI0715396B8 (pt) | método de produção de uma composição para vacina | |
| BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
| CO6160335A2 (es) | Vacuna | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| MX2020005235A (es) | Celula humana transformada y uso de la misma. | |
| DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
| MX2024012807A (es) | Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas | |
| AR126239A1 (es) | Región 5 no traducida y región 3 no traducida no naturales y uso de estas | |
| BR112015019873A2 (pt) | inibidores macrocíclicos da lrrk2 cinase | |
| BR112022022859A2 (pt) | Vacinas contra sars-cov-2 | |
| BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
| BR112015021523A8 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| BR112023016241A2 (pt) | Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos | |
| BR112016005417A8 (pt) | "compostos derivados de desoxinojirimicina, composição farmacêutica e seus usos" | |
| MX2023007229A (es) | Constructo de arn. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| MX2024002913A (es) | Anticuerpos anti-siglec-6 y metodos de uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |